Skip to content

Innoviva, Inc. INVA Free cash flow margin

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Merck & Co. logo
Merck & Co.MRK
21.5%-5.2pp
AbbVie logo
AbbVieABBV
31.8%+5.0pp
Insmed logo
InsmedINSM
-112.5%-35.3pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-77.4%+35.3pp
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
44.8%+16.8pp

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Innoviva, Inc.’s 10-Q, filed May 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s free cash flow margin?
Innoviva, Inc. (INVA) reported free cash flow margin of 54.1% in Q1 2025.
How has Innoviva, Inc.'s free cash flow margin changed year-over-year?
Innoviva, Inc.'s free cash flow margin increased by 10.8% year-over-year, from 48.8% to 54.1%.
What is the long-term trend for Innoviva, Inc.'s free cash flow margin?
Over 4 years (2020 to 2024), Innoviva, Inc.'s free cash flow margin has grown at a -13.3% compound annual growth rate (CAGR), from 93% to 52.5%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.